Next Science Ltd (ASX: NXS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Next Science Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$42.43 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
292.63 million
Earnings per share
-0.032
Dividend per share
N/A
Year To Date Return
100.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Next Science Ltd (ASX: NXS)
Latest News
Share Gainers
Why ANZ, Next Science, Macmahon, and Pointsbet shares are racing higher
Healthcare Shares
Guess which ASX healthcare share is booming 28% on a sales boost
Healthcare Shares
Next Science shares defy ASX market slump to surge 8%
Healthcare Shares
Here's why the Next Science (ASX:NXS) share price is rocketing 11% today
Healthcare Shares
What happened to the Next Science (ASX:NXS) share price last earnings season?
Share Gainers
Next Science (ASX:NXS) share price jumps on record revenue growth
Technology Shares
Next Science (ASX:NXS) share price swings on lowered earnings update
Healthcare Shares
Here's why the Next Science (ASX:NXS) share price finished higher today
Healthcare Shares
Next Science (ASX:NXS) share price falls despite 'exciting future ahead'
Share Gainers
Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher
Healthcare Shares
Why the Next Science (ASX:NXS) share price opened 40% higher
Share Fallers
Why Alumina, Delorean, Next Science, & Pushpay shares are tumbling lower
NXS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Next Science Ltd
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Jul 2025 | Harry Hall(IV) | Issued | 465,131 | $65,118 |
Conversion of securities.
|
| 14 Jul 2025 | Harry Hall(IV) | Exercise | 465,131 | $65,118 |
Conversion of securities. 22,79,525 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Grant Hummel | Non-Executive Director | Aug 2023 |
Mr Hummel has been a partner of an Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with expertise in advising primary care, allied health, medical device and life science clients. He is the Chair of People and Culture Committee.
|
| Ms Aileen Stockburger | Non-Executive DirectorNon-Executive Chairman | Oct 2018 |
Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's largest medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. She is a Member of the Risk, People & Culture Committee.
|
| Ms Katherine (Kathy) Ostin | Non-Executive Director | Oct 2023 |
Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the U.S., Asia, and the UK. She is Chair of the Risk Committee.
|
| Ms Gillian Maria Nairn | Company Secretary | Jun 2018 |
-
|
| Gillian Maria Nairn | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 58,460,457 | 20.01% |
| Auckland Trust Company Ltd <Second Pacific Master Superannuation Fund> | 56,019,938 | 19.17% |
| UBS Nominees Pty Ltd | 20,054,081 | 6.86% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 6,694,440 | 2.29% |
| Mr Charles Robert Dirck Wittenoom | 5,571,349 | 1.91% |
| S G Andrew Pty Ltd <S G Andrew Super Fund A/C> | 4,940,000 | 1.69% |
| Mr James Willis Mozley Jr | 4,676,732 | 1.60% |
| Citicorp Nominees Pty Limited | 4,671,979 | 1.60% |
| Mr James Fong Seeto | 4,600,000 | 1.57% |
| Dr Matthew Franco Myntti | 4,171,824 | 1.43% |
| J P Morgan Nominees Australia Pty Limited | 3,349,443 | 1.15% |
| Mr Dean Anthony Mackenzie | 3,187,175 | 1.09% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 2,921,187 | 1.00% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,852,962 | 0.98% |
| Bond Street Custodians Limited <Lam1 D08047 A/C> | 2,460,427 | 0.84% |
| Twenty Fifth Elporto Pty Ltd <Twenty Fifth Elporto Sf A/C> | 2,300,000 | 0.79% |
| Judith Lee Mitchell | 2,284,503 | 0.78% |
| Mrs Gwendoline Louise King & Mr Simon George Andrew | 2,000,000 | 0.68% |
| Belgravia Strategic Equities Pty Ltd | 1,965,000 | 0.17% |
| Mr Richard Hugo Hamersley <Greenidge A/C> | 1,947,596 | 0.65% |
